Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to 2022



Summary



GlobalData’s pharmaceuticals report, “Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to 2022” provides Torisel sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2022). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.



Scope


- Therapy area profile including patient population for the US and EU5
- Analysis and review of Rencarex including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Rencarex including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2012-2022 for Rencarex in the US and EU5



Reasons to buy


- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2014-2022 for all seven major markets

Table Of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Introduction 5
2.1 RCC 5
2.1.1 Types of Renal Cell Carcinoma 5
2.2 RCC Market 6
2.3 Epidemiology 6
2.4 Pathophysiology 9
2.5 Etiology 9
2.5.1 Cigarette Smoking 9
2.5.2 Obesity 10
2.5.3 Acquired Cystic Disease 10
2.5.4 Hypertension 10
2.5.5 Family History of Kidney Cancer 10
2.5.6 High Blood Pressure 10
2.5.7 Usage of Certain Medicines 10
2.5.8 Advanced Kidney Disease 10
2.5.9 Gender and Race 10
2.5.10 Genetic and Hereditary Risk Factors 11
2.5.11 Symptoms 11
2.5.12 Diagnosis 12
2.6 GlobalData Report Guidance 14
3 RCC Disease: Market Characterization 15
3.1 RCC Disease Market 15
3.2 RCC Disease Market Forecasts and CAGR 15
3.1 Drivers for the RCC Disease Market 15
3.1.1 High Incidence 16
3.1.2 High Prevalence 17
3.1.3 Emergence of Targeted Therapies 17
3.1.4 Large Unmet Need 17
3.2 Tumor-Node-Metastases (TNM) Classification of RCC 18
3.2.1 Staging 18
3.2.2 Grading 20
3.2.3 Prognosis 20
3.3 Treatment Options in RCC 21
3.3.1 Surgery 21
3.3.2 Radiation therapy 22
3.3.3 Chemotherapy 22
3.3.4 Targeted Therapies 22
3.3.5 Tyrosine Kinase Inhibitors 23
3.3.6 Mammalian Target of Rapamycin (mTOR) Inhibitor 23
3.3.7 Vascular Endothelial Growth Factor (VEGF) Inhibitor 24
3.3.8 Treatment by Stage 24
3.4 Classification of Patients with RCC 26
4 Rencarex 27
4.1 Introduction 27
4.2 Mechanism of Action 27
4.3 Clinical Studies 27
4.4 Factors Affecting Sales of Rencarex 28
4.4.1 High Efficacy 28
4.4.2 Excellent Safety Profile 28
4.4.3 Large Unmet Need 28
4.4.4 Orphan Drug Status 28
4.5 Drug Evaluation 29
4.5.1 Drug Risk Benefit Score 29
4.5.2 Intensity of Competition 29
4.6 Sales Forecasts 30
4.6.1 Target Patient Pool of Rencarex 30
4.6.2 Dosing 30
4.6.3 Market Penetration 31
4.6.4 Annual Cost of Therapy 31
4.6.5 Sales Projections of Rencarex 32
5 RCC Market: Appendix 40
5.1 Market Definitions 40
5.2 Abberiviations 40
5.3 Research Methodology 41
5.3.1 Coverage 41
5.3.2 Secondary Research 41
5.3.3 Forecasting 41
5.3.4 Number of Patients Approved to Take the Drug 42
5.3.5 Net Penetration of Drug 42
5.3.6 Net Annual Dosing 42
5.3.7 Annual Cost of Therapy 42
5.4 Drug Sales Estimates Model 43
5.5 Contact Us 43
5.6 Disclaimer 43
5.7 Sources 44

List of Tables

Table 1: RCC, Incidences and Mortality, 2008-2030 8
Table 2: RCC, TNM Classification 18
Table 3: RCC, Fuhrman grading system 20
Table 4: RCC, Treatment Guidelines 21
Table 5: Rencarex, Renal Cell Carcinoma, Phase II Clinical Study Results 28
Table 6: Rencarex, Renal Cell Carcinoma, Global, Sales Estimates ($m), 2014-2022 32
Table 7: Rencarex, Renal Cell Carcinoma, The US, Sales Estimates ($m), 2014-2022 33
Table 8: Rencarex, Renal Cell Carcinoma, The UK, Sales Estimates ($m), 2014-2022 34
Table 9: Rencarex, Renal Cell Carcinoma, France, Sales Estimates ($m), 2014-2022 35
Table 10: Rencarex, Renal Cell Carcinoma, Germany, Sales Estimates ($m), 2014-2022 36
Table 11: Rencarex, Renal Cell Carcinoma, Italy, Sales Estimates ($m), 2014-2022 37
Table 12: Rencarex, Renal Cell Carcinoma, Spain, Sales Estimates ($m), 2014-2022 38

List of Figures

Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2010 7
Figure 2: Total number of cigarettes consumed, The US, 1976-2006 9
Figure 3: RCC, Global, Market Size Forecasts ($bn), 2010-2022 15
Figure 4: RCC, Global, Incidence (in million), 2008-2030 16
Figure 5: Oncology, Worldwide, Incidence (in million), 2008-2030 16
Figure 6: Classification of Patients with RCC 26
Figure 7: Renal Cell Carcinoma, Rencarex, Drug Model Diagram 30
Figure 8: Rencarex, Renal Cell Carcinoma, Global, Sales Estimates ($m), 2014-2022 32
Figure 9: Rencarex, Renal Cell Carcinoma, The US, Sales Estimates ($m), 2014-2022 33
Figure 10: Rencarex, Renal Cell Carcinoma, The UK, Sales Estimates ($m), 2014-2022 34
Figure 11: Rencarex, Renal Cell Carcinoma, France, Sales Estimates ($m), 2014-2022 35
Figure 12: Rencarex, Renal Cell Carcinoma, Germany, Sales Estimates ($m), 2014-2022 36
Figure 13: Rencarex, Renal Cell Carcinoma, Italy, Sales Estimates ($m), 2014-2022 37
Figure 14: Rencarex, Renal Cell Carcinoma, Spain, Sales Estimates ($m), 2014-2022 38
Figure 15: Rencarex, Renal Cell Carcinoma, Global, Sales Distribution by Country (%), 2022 39
Figure 16: Patients Approved for the Drug 42

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 Summary Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, ...

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Neurostimulation: Technologies and Global Markets

Neurostimulation: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • March 2014
  • by BCC Research

REPORT HIGHLIGHTS The global neurostimulation devices market is expected to reach $3.8 billion in 2013 and $4.1 billion in 2018, with a compound annual growth rate (CAGR) of 1.5%. This report provides: ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.